Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A01N-043/08
A01N-043/58
A01N-043/60
A01N-043/90
A61K-031/34
A61K-031/50
A61K-031/495
A61K-031/519
C07D-473/00
출원번호
US-0630589
(2005-06-25)
등록번호
US-8124653
(2012-02-28)
국제출원번호
PCT/US2005/022866
(2005-06-25)
§371/§102 date
20070207
(20070207)
국제공개번호
WO2006/004719
(2006-01-12)
발명자
/ 주소
Matalon, Reuben
Matalon, Ofer
출원인 / 주소
The Board of Regents of The University of Texas System
대리인 / 주소
Landrum Intellectual Property
인용정보
피인용 횟수 :
2인용 특허 :
18
초록▼
Disclosed is a composition that includes a tetrahydrobiopterin in a controlled-release pharmaceutical preparation. Also disclosed is a method of treating a patient with phenylketonuria that includes administering, to the patient, a composition that contains tetrahydrobiopterin in a controlled-releas
Disclosed is a composition that includes a tetrahydrobiopterin in a controlled-release pharmaceutical preparation. Also disclosed is a method of treating a patient with phenylketonuria that includes administering, to the patient, a composition that contains tetrahydrobiopterin in a controlled-release pharmaceutical preparation. Also disclosed is a method of treating a patient with ADHD that includes administering a tetrahydropterin to the patient. Compositions for the treatment of ADHD are also described.
대표청구항▼
1. A method of treating a patient with attention deficit hyperactivity disorder (ADHD), said method comprising administering a tetrahydropterin to a patient in need thereof. 2. A method according to claim 1, further comprising: administering a compound selected from the group consisting of methylphe
1. A method of treating a patient with attention deficit hyperactivity disorder (ADHD), said method comprising administering a tetrahydropterin to a patient in need thereof. 2. A method according to claim 1, further comprising: administering a compound selected from the group consisting of methylphenidate, clonidine, an amphetamine, pemoline, and combinations thereof. 3. A method according to claim 2, wherein the tetrahydropterin and the compound are co-administered. 4. A method according to claim 2, wherein the tetrahydropterin and the compound are co-administered in a single dosage form. 5. A method according to claim 1, wherein said method does not involve coadministering methylphenidate, clonidine, an amphetamine, and/or pemoline. 6. A method according to claim 1, further comprising: administering a compound that mimics catecholamine and/or serotonin. 7. A method according to claim 6, wherein the tetrahydropterin and the compound are co-administered. 8. A method according to claim 6, wherein the tetrahydropterin and the compound are co-administered in a single dosage form. 9. A method according to claim 1, wherein said method does not involve coadministering a compound that mimics catecholamine and/or serotonin. 10. A method according to claim 1, further comprising: administering a compound selected from the group consisting of N-acetyltyrosine, pyridoxal 5-phosphate, and combinations thereof. 11. A method according to claim 10, wherein the tetrahydropterin and the compound are co-administered. 12. A method according to claim 10, wherein the tetrahydropterin and the compound are co-administered in a single dosage form. 13. A method according to claim 1, wherein said method does not involve coadministering N-acetyltyrosine and/or pyridoxal 5-phosphate. 14. A method according to claim 1, further comprising: administering a compound selected from the group consisting of acetylcarnitine, pyridoxal 5-phosphate, and combinations thereof. 15. A method according to claim 14, wherein the tetrahydropterin and the compound are co-administered. 16. A method according to claim 14, wherein the tetrahydropterin and the compound are co-administered in a single dosage form. 17. A method according to claim 1, wherein said method does not involve coadministering acetylcarnitine and/or pyridoxal 5-phosphate. 18. A method according to claim 1, wherein the tetrahydropterin is a tetrahydropterin substituted in the 6-position with a —CH(OH)—CH(OH)—CH3—, moiety. 19. A method according to claim 1, wherein the tetrahydropterin is tetrahydrobiopterin. 20. A method according to claim 1, wherein the tetrahydropterin is a tetrahydropterin substituted in the 6-position with a substituted or unsubstituted, branched or unbranched, cyclic or non-cyclic, aliphatic or aromatic hydrocarbon, halide, oxyether, thioether, or anhydride moiety. 21. A method according to claim 1, wherein the tetrahydropterin is a tetrahydropterin substituted in the 6-position with a substituted or unsubstituted, branched or unbranched aliphatic hydrocarbon moiety. 22. A method according to claim 1, wherein the tetrahydropterin is a tetrahydropterin substituted in the 6-position with a methyl group.
Carla Marcella Caramella IT; Maria Cristina Bonferoni IT, Complex between carrageenan and a water soluble drug having a specific granulometry and relative controlled release pharamaceutical compositions.
David B. Masters, Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices.
Krishnan, Ranga R.; Caron, Marc G.; Zhang, Xiaodong; Beaulieu, Martin; Gainetdinova, Raul R.; Sotnikova, Tatiana D., Method for augmenting the effects of serotonin reuptake inhibitors.
Randolph Theodore W. ; Lengsfeld Corinne ; Falk ; III Richard Frank, Microparticles of lactide-co-glycolide copolymers and methods of making and using the same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.